AEMD

Aethlon Medical, Inc. develops therapeutic devices focused on addressing life-threatening diseases through blood purification technology. Headquartered in San Diego, California, the clinical-stage company specializes in the Aethlon Hemopurifier, a medical device designed to eliminate life-threatening viruses and tumor-derived exosomes from blood. The Hemopurifier platform utilizes lectin-based affinity to capture and remove harmful particles from the circulatory system, targeting applications in cancer, viral infections, and other immune-related conditions. The company's primary focus centers on advancing the Hemopurifier through clinical trials for various indications, including solid tumors and life-threatening viral pathogens. Aethlon has received FDA breakthrough device designation for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard-of-care therapy, and for life-threatening viruses not addressable with approved therapies. The company operates as a development-stage enterprise with limited commercial revenue, funding operations primarily through equity financing and grants. Aethlon collaborates with leading medical institutions to conduct clinical studies and validate its technology platform. The company maintains a small workforce focused on device development, regulatory advancement, and clinical trial execution. As a publicly traded entity, Aethlon continues to pursue regulatory milestones and partnership opportunities to advance its blood purification platform toward potential commercialization.